Inicio>>Signaling Pathways>> Others>>Acebilustat

Acebilustat (Synonyms: CTX-4430)

Catalog No.GC19018

El acebilustato (CTX-4430) es un inhibidor de la hidrolasa de leucotrieno A4, utilizado como fÁrmaco antiinflamatorio oral.

Products are for research use only. Not for human use. We do not sell to patients.

Acebilustat Chemical Structure

Cas No.: 943764-99-6

Tamaño Precio Disponibilidad Cantidad
1mg
31,00 $
Disponible
5mg
99,00 $
Disponible
10mg
135,00 $
Disponible
25mg
270,00 $
Disponible
50mg
432,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Acebilustat is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug.

Acebilustat is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial[1]. Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils[2].

References:
[1]. Elborn JS, et al. Phase 1 Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2016 Nov 2.
[2]. Elborn JS, et al. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2016 Oct 28.

Reseñas

Review for Acebilustat

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Acebilustat

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.